CSI Market
Sign In | Register

Cymabay Therapeutics Inc (CBAY) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CBAY Annual Cash Flow →
Cash flow data covering Cymabay Therapeutics Inc–Dec 31 2022 offers a view into how Dec 31 2023's cash position has developed alongside business activity.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Dec 31 2023)
12 Months 		(Sep 30 2023) (Jun 30 2023) (Mar 31 2023) (Dec 31 2022)
Operating Activities
Income-105.37
Depreciation & amortization0.68
Amortization of Other Assets0.00
Increase (Decrease) in Deferred Revenue2.79
Increase (Decrease) in Restructuring Reserve0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment0.00
Share-based Compensation15.23
Income (Loss) from Equity Method Investments0.00
Fair Value Adjustment of Warrants0.00
Accretion Of Tenant Improvement Allowance-
Accelerated Vesting Of Stock Based Compensation Expense Due To Restructuring-
Increase Decrease Ininterest Receivable And Other Current Assets-
Increase Decrease In Prepaid Research And Development And Other Prepaid Expenses-
Cashless Exercise Of Common Stock For Warrants Liability-
Increase Decrease In Other Prepaid Expense And Current Assets-
Accretion Of Development Financing Liability13.86
Noncash Lease Expense-0.70
Income taxes0.00
Losses/ -gains on Investments net0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable2.73
Increase (Decrease) in Other Accrued Liabilities7.86
Deferred Revenue and Customer Advances and Deposits0.00
Increase (Decrease) in Prepaid Expense and Other Assets-6.96
Other Working Capital0.11
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-8.76
Discontinued operations0.00
Net Cash flow from Operating Activities-72.53
Investing Activities
Capital Expenditures-0.45
Sale of Capital Items0.00
Proceeds from Sale and Maturity of Marketable Securities219.55
Payments to Acquire Marketable Securities-305.67
Real Estate Investments0.00
Proceeds From Maturities Of Marketable Securities-
Proceeds From Sale Of Marketable Securities-
Proceeds From Sale Of Marke Table Securities-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities-86.57
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.00
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock10.63
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Development Financing Net Of Transaction Costs-
Proceeds From Issuance Of Common Stock And Prefundeded Warrants335.58
Proceeds From Development Financing Net O Ftransaction Costs-
Proceeds From Development Financing-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities345.77
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-72.98
Total Cash Flow186.67
4 historic quarters locked

Sign in to unlock the full Cymabay Therapeutics Inc cash flow history.

Sign In Create Free Account

About Cymabay Therapeutics Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20231231)
  • Filed with the SEC: February 28, 2024
  • Source: d719301d10k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001193125-24-050758

Figures are derived from filed reports and may be restated. Historical data is subject to revision.